177 related articles for article (PubMed ID: 29790143)
1. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
2. Endocrinopathies with use of cancer immunotherapies.
Villa NM; Farahmand A; Du L; Yeh MW; Smooke-Praw S; Ribas A; Chmielowski B; Cherry G; Leung AM
Clin Endocrinol (Oxf); 2018 Feb; 88(2):327-332. PubMed ID: 28941311
[TBL] [Abstract][Full Text] [Related]
3. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
Zhang S; Liu J; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):623-628. PubMed ID: 28935016
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Qiu J; Cheng Z; Jiang Z; Gan L; Zhang Z; Xie Z
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791528
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.
Ding P; Liu P; Meng L; Zhao Q
Eur J Med Res; 2023 Nov; 28(1):492. PubMed ID: 37936161
[TBL] [Abstract][Full Text] [Related]
7. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.
Fukushima T; Kobayashi S; Ueno M
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38769817
[TBL] [Abstract][Full Text] [Related]
8. Tislelizumab (Tevimbra) for esophageal cancer.
Med Lett Drugs Ther; 2024 May; 66(1702):e85-e86. PubMed ID: 38771731
[No Abstract] [Full Text] [Related]
9. Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies.
Kong Y; Wang X; Qie R
Front Oncol; 2024; 14():1347140. PubMed ID: 38482205
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review.
Fan Y; Zhao J; Mi Y; Zhang Z; Geng Y; Zhou L; Shen L; Zhang Z
J Immunother; 2023 Nov-Dec 01; 46(9):341-345. PubMed ID: 37721343
[TBL] [Abstract][Full Text] [Related]
11. When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy.
Tayyeb M; Tariq M; Khan AM; Khalid F; Meghal T; Du D
J Community Hosp Intern Med Perspect; 2023; 13(6):90-94. PubMed ID: 38596553
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma.
Birnbaum MR; Ma MW; Fleisig S; Packer S; Amin BD; Jacobson M; McLellan BN
JAAD Case Rep; 2017 May; 3(3):208-211. PubMed ID: 28443311
[No Abstract] [Full Text] [Related]
13. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Gettinger S; Hellmann MD; Chow LQM; Borghaei H; Antonia S; Brahmer JR; Goldman JW; Gerber DE; Juergens RA; Shepherd FA; Laurie SA; Young TC; Li X; Geese WJ; Rizvi N
J Thorac Oncol; 2018 Sep; 13(9):1363-1372. PubMed ID: 29802888
[TBL] [Abstract][Full Text] [Related]
15. Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.
Shalata W; Attal ZG; Shhadi R; Abu Salman A; Abu Jama A; Shalata S; Halumi K; Yakobson A
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003995
[TBL] [Abstract][Full Text] [Related]
16. [Managing the Adverse Effects Related to Immune Checkpoint Inhibitors].
Kuo HH; Chen WW
Hu Li Za Zhi; 2018 Jun; 65(3):88-95. PubMed ID: 29790143
[TBL] [Abstract][Full Text] [Related]
17. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
18. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
19. Managing adverse effects of immunotherapy.
Gerson JN; Ramamurthy C; Borghaei H
Clin Adv Hematol Oncol; 2018 May; 16(5):364-374. PubMed ID: 29851932
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
